U.K. gatekeepers doubt the value of Millennium Crohn's med

The U.K.'s cost-effectiveness watchdog says it's not planning to recommend a new Crohn's disease treatment from Millennium Pharmaceuticals. The National Institute for Health and Care Excellence (NICE) cited uncertain evidence for the drug, Entyvio, and said it's unlikely it would be a good value for the National Health Service. The draft decision comes despite the Takeda unit's offer of a discount. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

Telehealth is surging during the pandemic, however, pharma companies’ place in the booming practice is still emerging.

Merck is expanding its cancer awareness effort with journalist Katie Couric to include survivorship and screening topics and a new podcast next month.